Quick Answer
Sana Biotechnology, Inc. reported R&D Expense of $131.98 million for fiscal year 2025.
Sana Biotechnology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $131.98M | -38.8% |
| 2024 | $215.67M | -17.6% |
| 2023 | $261.81M | -8.4% |
| 2022 | $285.88M | +15.0% |
| 2021 | $248.63M | +87.0% |
| 2020 | $132.94M | +33.5% |
| 2019 | $99.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.11M | -43.4% | +1.2% |
| June 30, 2025 | $29.76M | -51.1% | -20.0% |
| March 31, 2025 | $37.19M | -34.1% | -30.1% |
| September 30, 2024 | $53.21M | -18.9% | -12.6% |
| June 30, 2024 | $60.87M | -16.7% | +7.8% |
| March 31, 2024 | $56.45M | -16.0% | -14.0% |
| September 30, 2023 | $65.61M | -14.5% | -10.2% |
| June 30, 2023 | $73.04M | +0.7% | +8.8% |
- Sana Biotechnology, Inc. showed a decrease of -38.8% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Sana Biotechnology, Inc.’s r&d expense has grown by 32.5% (from $99.59 million to $131.98 million).
- The most recent figure is from Sana Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: